CoChat

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk

Open access
Pistilli, Barbara, Paci, Angelo, Ferreira, Arlindo R., Di Meglio, Antonio, Poinsignon, Vianney, Bardet, Aurelie, Menvielle, Gwenn, Dumas, Agnes, Pinto, Sandrine, Dauchy, Sarah, Fasse, Leonor, Cottu, Paul H., Lerebours, Florence, Coutant, Charles, Lesur, Anne, Tredan, Olivier, Soulie, Patrick, Vanlemmens, Laurence, Jouannaud, Christelle, Levy, Christelle, Everhard, Sibille, Arveux, Patrick, Martin, Anne Laure, Dima, Alexandra, Lin, Nancy U., Partridge, Ann H., Delaloge, Suzette, Michiels, Stefan, André, Fabrice, Vaz-Luis, Ines · 2020 · Journal of Clinical Oncology
Cited by 147

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

PURPOSE: Nonadherence to long-term treatments is often under-recognized by physicians and there is no gold standard for its assessment. In breast cancer, nonadherence to tamoxifen therapy after surgery constitutes a major obstacle to optimal outcomes. We sought to evaluate the rate of biochemical nonadherence to adjuvant tamoxifen using serum assessment and to examine its effects on short-term, distant disease-free survival (DDFS). PATIENTS AND METHODS: We studied 1,177 premenopausal women enrolled in a large prospective study (CANTO/NCT01993498). Definition of biochemical nonadherence was based on a tamoxifen serum level < 60 ng/mL, assessed 1 year after prescription. Self-reported nonadherence to tamoxifen therapy was collected at the same time through semistructured interviews. Survival analyses were conducted using an inverse probability weighted Cox proportional hazards model, using a propensity score based on age, staging, surgery, chemotherapy, and center size. RESULTS: Serum assessment of tamoxifen identified 16.0% of patients (n = 188) below the set adherence threshold. Patient-reported rate of nonadherence was lower (12.3%). Of 188 patients who did not adhere to the tamoxifen prescription, 55% self-reported adherence to tamoxifen. After a median follow-up of 24.2 months since tamoxifen serum assessment, patients who were biochemically nonadherent had significantly shorter DDFS (for distant recurrence or death, adjusted hazard ratio, 2.31; 95% CI, 1.05 to 5.06; P = .036), with 89.5% of patients alive without distant recurrence at 3 years in the nonadherent cohort versus 95.4% in the adherent cohort. CONCLUSION: Therapeutic drug monitoring may be a useful method to promptly identify patients who do not take adjuvant tamoxifen as prescribed and are at risk for poorer outcomes. Targeted interventions facilitating patient adherence are needed and have the potential to improve short-term breast cancer outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.01758

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 147

Metadata

Authors
Pistilli, B., Paci, A., Ferreira, A. R., Di Meglio, A., Poinsignon, V., Bardet, A., Menvielle, G., Dumas, A., Pinto, S., Dauchy, S., Fasse, L., Cottu, P. H., Lerebours, F., Coutant, C., Lesur, A., Tredan, O., Soulie, P., Vanlemmens, L., Jouannaud, C., Levy, C., Everhard, S., Arveux, P., Martin, A. L., Dima, A., Lin, N. U., Partridge, A. H., Delaloge, S., Michiels, S., André, F., & Vaz-Luis, I.
Venue
Journal of Clinical Oncology
Published
2020-08-20
Volume
38
Issue
24
Pages
2762-2772
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3036415919
Cited by
147
References
10
FWCI
20.40
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.